No Data
Lepu Healthcare: 2024 Annual Results Forecast
Lepu Medical Technology (300003.SZ) plans to invest no more than 0.2 billion yuan to participate in the establishment of a healthcare industry merger and acquisition Fund in Suzhou.
Lepu Medical Technology (300003.SZ) announced that the company has cooperated with the professional investment institution Suzhou Lepu Suwing Consulting Partnership (has...
Shengnuo Biotechnology (688117.SH): Lepu Medical Technology has cumulatively reduced its shareholding by 0.7912%.
On December 26, Gelonghui reported that Shengnuo Biology (688117.SH) announced that the company recently received a notification letter from Lepu Medical Technology regarding the results of shareholding reduction. As of the date of this announcement, Lepu Medical Technology has cumulatively reduced its shareholding by 889,445 shares through centralized bidding, accounting for 0.7912% of the company's total share capital. After the reduction, Lepu Medical Technology holds 5,272,000 shares of the company, accounting for 4.6896% of the company's total share capital, and this shareholding reduction plan has reached its expiration.
Lepu Medical Technology (300003.SZ): The transcatheter implanted aortic valve system has received registration approval.
Lepu Medical Technology (300003.SZ) announced that its subsidiary Lepu Xintai's product ScienCro ...
Lepu Biopharma Renews Procurement Contract With Controlling Shareholder
Lepu Biotech-B (02157.HK) has signed a CDMO service framework agreement with lepu medical technology.
On November 26, Gleam Hill reported that on November 26, 2024, the company entered into a CDMO service framework agreement with lepu medical technology, pursuant to which the company and/or its subsidiaries agreed to provide CDMO technical services and related supporting equipment to lepu medical technology and/or its subsidiaries.
